contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


wrap-up-from-interview-with-deputy-ceo-julie-waras-brogren

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

CEO, Sweden

Claus Thestrup

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.

Ascelia Pharma

Wrap-Up from Interview with Deputy CEO Julie Waras Brogren

We recently hosted an event in conjunction with the Q3 report and the announcement of the full data package completion for the Phase 3 Orviglance &#x2013; SPARKLE study.
As Ascelia Pharma prepare for the pre-submission meeting with the FDA and the planned NDA filing for Orviglance in mid-2025, investors should anticipate an increase in costs. To support this, the company conducted a fully subscribed rights issue in Q3, raising SEK 105 million gross. Additionally, further funding is expected from the TO1 warrant in April 2025, which, if fully subscribed, could bring in another SEK 70 million. Beyond funding efforts, Ascelia Pharma is in active discussions with potential partners for the full commercialization of Orviglance. Terms have not yet been announced but are expected to include milestone payments and royalties.
Orviglance addresses an unmet need in liver imaging for cancer patients with severe kidney impairment, a market valued at approximately USD 800 million, with half of the potential in the U.S.
Deputy CEO Julie W. Brogren shared two highly insightful slides, presenting the primary and secondary endpoints from the full study report.
Primary endpoint:
<img src="https://content.inderes.se/assets/36ea5a34-48dd-4767-ad8b-15ff55181149?width=1293&amp;height=626" alt="Ascelia Primary">
Secondary endpoint:
<img src="https://content.inderes.se/assets/52fef17b-6096-4b9f-9d60-f15b077f4eaf?width=1280&amp;height=623" alt="Ascelia Secondary">
With strong data on both primary and secondary endpoints, a robust balance sheet, and promising partnership discussions, Ascelia Pharma is well-positioned to achieve its milestone objectives.
Listen to the interview here: <a href=" https://www.youtube.com/watch?v=OcDcfzHXj_4" target="_blank" rel="noopener">Ascelia Pharma interview</a>
Disclaimer: HC Andersen Capital receives payment from the Ascelia Pharma for a Digital IR/Corporate Visibility subscription agreement. Analyst Claus Thestrup 8:15 AM, 14.11.2024

HC Andersen Capital

Return on capital (ROE, ROI, ROIC, RONIC)

Drug development investment: Value creation through M&As and licensing agreements

What does negative working capital mean and why is it a good thing?

Income statement

Amazon and Costco in Sweden: A looming threat that Nordic retailers ignore at their peril

Ascelia Pharma

Stay up to date with our newsletter